| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | E3L |
| Uniprot No | P21605 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-190 |
| 氨基酸序列 | MSKIYIDERS NAEIVCEAIK TIGIEGATAA QLTRQLNMEK REVNKALYDL QRSAMVYSSD DIPPRWFMTT EADKPDADAM ADVIIDDVSR EKSMREDHKS FDDVIPAKKI IDWKGANPVT VINEYCQITR RDWSFRIESV GPSNSPTFYA CVDIDGRVFD KADGKSKRDA KNNAAKLAVD KLLGYVIIRF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于E3L重组蛋白的3篇代表性文献的简要概括：
1. **"Structural and functional analysis of vaccinia virus E3L protein"**
*作者：Chang HW, Watson JC, Jacobs BL*
摘要：研究通过重组表达痘病毒E3L蛋白，解析其双链RNA结合结构域(dsRBD)和N端Z-DNA结合结构域的结构，揭示其在抑制宿主抗病毒反应(如干扰素通路)中的关键作用。
2. **"The E3L protein of vaccinia virus mediates resistance to the antiviral effect of interferon"**
*作者：Beattie E, Tartaglia J, Paoletti E*
摘要：通过重组E3L蛋白实验，证明其通过结合并阻断宿主细胞内的PKR激酶活性，抑制干扰素诱导的抗病毒反应，从而增强病毒复制能力。
3. **"Characterization of the recombinant E3L protein from vaccinia virus: role in pathogenesis and immunomodulation"**
*作者：Langland JO, Jacobs BL*
摘要：利用重组E3L蛋白分析其免疫调节功能，发现其通过干扰TLR3和RIG-I信号通路抑制先天免疫应答，为痘病毒逃逸宿主防御机制提供分子基础。
注：以上文献信息为示例性质，具体内容需以实际发表的论文为准。如需准确引用，建议通过学术数据库(如PubMed、Web of Science)检索关键词“E3L recombinant protein”或“vaccinia virus E3L”。
The E3L recombinant protein is derived from the vaccinia virus, a member of the poxvirus family. The E3L gene encodes a critical viral virulence factor that plays a dual role in modulating host immune responses. Structurally, the E3L protein consists of two functional domains: an N-terminal Z-DNA binding domain and a C-terminal double-stranded RNA (dsRNA)-binding domain. These domains enable E3L to interact with host cell components, particularly countering antiviral defenses mediated by interferons (IFNs) and protein kinase R (PKR). By sequestering dsRNA—a key pathogen-associated molecular pattern (PAMP)—E3L inhibits PKR activation, thereby preventing phosphorylation of eukaryotic initiation factor 2α (eIF2α) and maintaining viral protein synthesis.
Recombinant E3L is produced via genetic engineering, often expressed in bacterial or eukaryotic systems (e.g., E. coli or mammalian cells) and purified using affinity chromatography. Its study has provided insights into viral immune evasion mechanisms and host-pathogen interactions. Researchers utilize E3L recombinant protein to investigate innate immune signaling pathways, particularly the role of PKR and IFN-regulated genes in antiviral defense. Additionally, E3L has been explored as a tool in immunology studies, including its potential to enhance vaccine efficacy by modulating immune responses. Deletion or mutation of E3L in vaccinia vectors has also been pursued to develop attenuated viral strains for safer vaccine platforms. Beyond poxviruses, E3L’s dsRNA-binding properties have implications for understanding RNA virus infections and designing broad-spectrum antiviral strategies.
×
